129 related articles for article (PubMed ID: 29955768)
1. Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial.
Danilenko M; Stamp E; Stocken DD; Husain A; Zangarini M; Cranston A; Stones R; Sinclair N; Hodgson K; Bowett SA; Roblin D; Traversa S; Plummer R; Veal G; Langtry JAA; Ashworth A; Burn J; Rajan N
JAMA Dermatol; 2018 Aug; 154(8):913-921. PubMed ID: 29955768
[TBL] [Abstract][Full Text] [Related]
2. Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.
Cranston A; Stocken DD; Stamp E; Roblin D; Hamlin J; Langtry J; Plummer R; Ashworth A; Burn J; Rajan N
Trials; 2017 Mar; 18(1):111. PubMed ID: 28270164
[TBL] [Abstract][Full Text] [Related]
3. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
4. Diverse presentations of cutaneous mosaicism occur in CYLD cutaneous syndrome and may result in parent-to-child transmission.
Arefi M; Wilson V; Muthiah S; Zwolinski S; Bajwa D; Brennan P; Blasdale K; Bourn D; Burn J; Santibanez-Koref M; Rajan N
J Am Acad Dermatol; 2019 Dec; 81(6):1300-1307. PubMed ID: 31085270
[TBL] [Abstract][Full Text] [Related]
5. Tumor mapping in 2 large multigenerational families with CYLD mutations: implications for disease management and tumor induction.
Rajan N; Langtry JA; Ashworth A; Roberts C; Chapman P; Burn J; Trainer AH
Arch Dermatol; 2009 Nov; 145(11):1277-84. PubMed ID: 19917957
[TBL] [Abstract][Full Text] [Related]
6. Tracking tumor kinetics in patients with germline CYLD mutations.
Brown S; Worthy SA; Langtry JAA; Rajan N
J Am Acad Dermatol; 2018 Nov; 79(5):949-951. PubMed ID: 29660420
[No Abstract] [Full Text] [Related]
7. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
Wataya-Kaneda M; Nakamura A; Tanaka M; Hayashi M; Matsumoto S; Yamamoto K; Katayama I
JAMA Dermatol; 2017 Jan; 153(1):39-48. PubMed ID: 27837201
[TBL] [Abstract][Full Text] [Related]
9. Phenotype variability in tumor disorders of the skin appendages associated with mutations in the CYLD gene.
Parren LJMT; Giehl K; van Geel M; Frank J
Arch Dermatol Res; 2018 Sep; 310(7):599-606. PubMed ID: 29974194
[TBL] [Abstract][Full Text] [Related]
10. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
11. A novel large deletion of the CYLD gene causes CYLD cutaneous syndrome in a Chinese family.
Zhu R; Xu J; Shen J; Li W; Tan F; Li C; Wei Z; Liu Y; Bai Y
Mol Genet Genomic Med; 2020 Oct; 8(10):e1441. PubMed ID: 32783365
[TBL] [Abstract][Full Text] [Related]
12. CYLD-mutant cylindroma-like basaloid carcinoma of the anus: a genetically and morphologically distinct class of HPV-related anal carcinoma.
Williams EA; Montesion M; Sharaf R; Corines J; Patel PJ; Gillespie BJ; Pavlick DC; Sokol ES; Alexander BM; Williams KJ; Elvin JA; Ross JS; Ramkissoon SH; Hemmerich AC; Tse JY; Mochel MC
Mod Pathol; 2020 Dec; 33(12):2614-2625. PubMed ID: 32461623
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
[TBL] [Abstract][Full Text] [Related]
14. Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours.
Rajan N; Elliott R; Clewes O; Mackay A; Reis-Filho JS; Burn J; Langtry J; Sieber-Blum M; Lord CJ; Ashworth A
Oncogene; 2011 Oct; 30(41):4243-60. PubMed ID: 21552290
[TBL] [Abstract][Full Text] [Related]
15. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Efficacy, Safety, and Tolerability of 3 Dose Regimens of Topical Sodium Nitrite With Citric Acid in Patients With Anogenital Warts: A Randomized Clinical Trial.
Ormerod AD; van Voorst Vader PC; Majewski S; Vanscheidt W; Benjamin N; van der Meijden W
JAMA Dermatol; 2015 Aug; 151(8):854-61. PubMed ID: 25922903
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary Cylindromas in CYLD Cutaneous Syndrome: A Rare Differential Diagnosis of Pulmonary Adenoid Cystic Carcinoma.
Bülau JE; Kreipe HH; Jessen E; von Hardenberg S; Auber B; Grohé C; Leo F
Clin Lung Cancer; 2021 Nov; 22(6):e795-e798. PubMed ID: 33896728
[No Abstract] [Full Text] [Related]
18. Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial.
Tacastacas JD; Chan DV; Carlson S; Gerson SL; Dowlati A; Fu P; Lu K; Groft S; Rosenjack J; Honda K; McCormick TS; Cooper KD
JAMA Dermatol; 2017 May; 153(5):413-420. PubMed ID: 28199478
[TBL] [Abstract][Full Text] [Related]
19. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
[TBL] [Abstract][Full Text] [Related]
20. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T
Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
